Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net sales | $592.1 | $585.4 |
| Cost of goods sold | 282.7 | 279.4 |
| Gross profit | 309.4 | 306.0 |
| Selling, general and administrative expense | 212.4 | 208.8 |
| Research and development expense | 62.9 | 73.5 |
| Income from operations | 34.1 | 23.7 |
| Interest expense | 12.3 | 12.0 |
| Foreign currency exchange gains, net | (2.4) | (2.7) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's SG&A?
- Bio-Rad Laboratories (BIO) reported SG&A of $212.4M in Q1 2026.
- How has Bio-Rad Laboratories's SG&A changed year-over-year?
- Bio-Rad Laboratories's SG&A increased by 1.7% year-over-year, from $208.8M to $212.4M.
- What is the long-term trend for Bio-Rad Laboratories's SG&A?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's SG&A has grown at a -0.9% compound annual growth rate (CAGR), from $877.12M to $844.3M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Bio-Rad Laboratories's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude